Colorectal cancer screening, what the guidelines actually say

Colorectal cancer screening is one of the few cancer screenings where two major bodies, the U.S. Preventive Services Task Force and the American Cancer Society, largely agree, and where the disagreements that remain are documented and reasoned rather than hidden. This page summarizes what those guidelines say and where their evidence is stronger or weaker. It is a reference to the published recommendations, not advice about your own situation.

What this screening is and what it looks for

Colorectal cancer screening looks for cancer in the colon and rectum, and, in most tests, for the precancerous growths called polyps that can be found and removed before they ever become cancer. That second point is part of why screening works: it is not only early detection but, for the direct-visualization tests, prevention.

There is no single required test. The USPSTF and the CDC both describe a menu of accepted strategies, grouped into stool-based tests and direct-visualization tests:

• Stool-based tests look for blood or altered DNA in a stool sample: high-sensitivity guaiac fecal occult blood test (gFOBT) or fecal immunochemical test (FIT) every year, and the stool DNA test combined with FIT (FIT-DNA, also written sDNA-FIT) every 1 to 3 years (USPSTF).
• Direct-visualization tests examine the bowel wall: colonoscopy every 10 years, CT colonography (a “virtual” colonoscopy) every 5 years, and flexible sigmoidoscopy every 5 years, or every 10 years when paired with annual FIT.

The USPSTF does not rank one test above the others. It notes that clinicians and patients may weigh several factors, including how invasive a test is, how often it must be repeated, and what preparation it requires, in deciding which approach fits. Because a test only helps if it is actually completed on schedule, follow-through is part of the choice, not an afterthought.

Who and when, per the USPSTF

In its 2021 recommendation, the USPSTF addresses adults at average risk, meaning people without a personal history of colorectal cancer or certain polyps, without a diagnosis of inflammatory bowel disease, and without a known high-risk inherited syndrome or a strong family history. People outside that average-risk group follow different guidance and are not the subject of this page.

For average-risk adults, the Task Force sets its recommendations by age band:

• Ages 50 to 75: Grade A. The USPSTF concludes with high certainty that the net benefit of screening is substantial. Grade A is the strongest recommendation the Task Force issues.
• Ages 45 to 49: Grade B. The Task Force concludes with moderate certainty that screening has a moderate net benefit. It “recommends” screening for this group, one step below the high-certainty Grade A.
• Ages 76 to 85: Grade C. The Task Force recommends that clinicians “selectively offer” screening, taking into account a person’s overall health, prior screening history, and preferences, rather than screening everyone in this band routinely.

These age bands describe who is eligible under the guideline and how confident the evidence is, not an instruction that any particular person should be screened on a particular day. When and whether to screen, and with which test, is a conversation for a clinician who knows your history.

The test options and how they differ

The accepted tests trade off convenience against how much they do in a single sitting. A colonoscopy is the most involved: it needs bowel preparation and sedation, but it examines the entire colon and lets a clinician remove polyps in the same session, and, if it is normal, it is repeated only every 10 years. A stool-based test such as FIT is done at home with no preparation and no sedation, but it must be repeated every year, and a positive result is not an endpoint. A positive stool test needs to be followed by a colonoscopy to find the source; a screening program that stops at the abnormal stool test has not finished the job. CT colonography and flexible sigmoidoscopy sit between these poles on invasiveness and interval. The CDC and American Cancer Society describe the same test menu.

The evidence and its grade

The reason the grades differ by age is worth stating plainly, because it is a good example of how evidence and recommendations relate.

Screening reduces deaths from colorectal cancer; that conclusion is well supported. The most direct evidence, from randomized trials, comes from guaiac stool testing and from flexible sigmoidoscopy, both of which lowered colorectal cancer mortality in controlled studies. For colonoscopy and FIT, the Task Force relied more heavily on observational studies and on modeling, because randomized trials measuring deaths were not complete for those tests. This is why “screening works” and “every test has equally proven mortality data” are not the same statement.

The age split rests on this same distinction. For ages 50 to 75, the direct evidence is strong enough for high certainty, hence Grade A. For ages 45 to 49, there is far less direct trial evidence in that specific age group. The Task Force instead leaned on microsimulation modeling, which projected a favorable balance of benefit to harm from starting at 45, together with data showing that colorectal cancer incidence has been rising among adults younger than 50. That combination supports a Grade B, moderate certainty of a moderate benefit, rather than the Grade A given to the older band. Reading the 45 to 49 recommendation as resting on the same footing as the 50 to 75 recommendation would overstate the evidence.

Where the guidance differs

The recommendation to begin at 45 is newer and rests on a different evidence base than the long-standing recommendation to screen from 50 to 75. The USPSTF lowered its start age from 50 to 45 in 2021, and the American Cancer Society had independently moved its start age to 45 in its 2018 guideline update, which it classified as a “qualified” recommendation and based partly on modeling and on rising incidence in younger adults. For ages 76 to 85, both bodies treat screening as an individualized decision rather than a routine one, weighing life expectancy, prior screening, and overall health. These are documented, reasoned differences and honest uncertainties, not settled certainties, and they are exactly the kind of nuance to raise with a clinician.

Questions to ask your clinician

Framed as questions to bring to a visit, not as steps to take on your own:

• Given my age, family history, and any prior results, what does the guideline eligibility mean for me, and when would screening reasonably start?
• Which test fits my situation, and what are the trade-offs between a colonoscopy and a stool-based test for someone like me?
• If I choose a stool-based test and it comes back positive, what is the next step, and how quickly should it happen?
• I am in the 45 to 49 band; how should I weigh the fact that this recommendation rests more on modeling than on direct trials in my age group?
• At my age and overall health, is continued screening still likely to help me, or am I closer to the individualized 76 to 85 decision?
• Am I at average risk under these guidelines, or does something in my history put me in a different category with different advice?

You can compare this profile against the full Guideline Tracker, read the sibling profiles for breast cancer screening and lung cancer screening, or see how everyday choices fit alongside screening in the big levers.